Sale of Associate Company Stakes Boosts Last Year's Profit; Wuxi AppTec Projects Over 50 Billion Yuan in Revenue This Year

NightAirdropper · 2026-03-24T04:02:06+00:00

Pharmaron's 2025 annual report shows operating revenue of 45.456 billion yuan, up 15.84% year-over-year; net profit of approximately 19.151 billion yuan, up 102.65% year-over-year. Continuing operations revenue was 43.42 billion yuan, with revenue from US customers increasing 34.3%. The company projects 2026 revenue of 51.3 billion to 53 billion yuan, with continuing operations growth of 18%-22%.

NightAirdropper

2026-03-24 04:02:06

Abstract generation in progress

WuXi AppTec Financial News (Reporter Ding Shuang) reported on March 23 that WuXi AppTec released its 2025 annual report. During the reporting period, the company achieved operating revenue of 45.456 billion yuan, a year-on-year increase of 15.84%; net profit attributable to shareholders of the listed company was approximately 19.151 billion yuan, a year-on-year increase of 102.65%.

In the annual report, the company stated that the sale of part of its equity in the joint venture WuXi XDC Cayman Inc. and the gains from divesting certain businesses also contributed to the company’s profits. After excluding non-recurring gains and losses, the net profit attributable to the parent company increased by 32.56% year-on-year.

As of the end of December 2025, the company’s ongoing business order backlog was 58 billion yuan, a year-on-year increase of 28.8%. During the reporting period, the company’s revenue from ongoing businesses was 43.42 billion yuan, of which revenue from U.S. clients was 31.25 billion yuan, a 34.3% increase; revenue from European clients was 4.82 billion yuan, a 4% decrease; revenue from Chinese clients was 5.47 billion yuan, a 3.5% decrease; revenue from clients in other regions was 1.88 billion yuan, a 4.1% increase.

Looking at the business segments, in 2025, except for other businesses which declined by 23.78% year-on-year, revenue from WuXi AppTec’s chemistry, testing, and biology businesses all increased. Among them, the chemistry business achieved revenue of 36.47 billion yuan, a 25.5% increase. This growth was mainly driven by the continuous expansion of the small molecule CDMO pipeline. In 2025, the company’s small molecule D&M business revenue was 19.92 billion yuan, an increase of 11.4%.

According to WuXi AppTec Chairman and CEO Li Ge, the company expects that in 2026, total revenue will reach between 51.3 billion and 53 billion yuan, with ongoing business revenue growing rapidly by 18%–22% year-on-year, and adjusted free cash flow reaching between 10.5 billion and 11.5 billion yuan.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.